Jazz Pharmaceuticals plc
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.62B | $1.49B | $1.32B | $1.17B | $872.4M | $586.0M | $272.3M | $173.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $198.4M | $162.3M | $135.3M | $85.2M | $41.6M | $20.5M | $14.1M | $25.6M |
| SG&A Expense | $544.2M | $502.9M | $449.1M | $406.1M | $304.3M | $223.9M | $108.9M | $69.0M |
| Operating Income | $528.8M | $591.7M | $508.2M | $195.6M | $340.3M | $197.8M | $127.8M | $57.8M |
| Operating Margin | 32.7% | 39.8% | 38.4% | 16.7% | 39.0% | 33.8% | 46.9% | 33.3% |
| Interest Expense | $37.8M | $27.5M | $26.5M | — | — | — | $1.7M | $12.7M |
| Pretax Income | $441.1M | $532.4M | $435.9M | $151.6M | $308.0M | $177.4M | $125.0M | $32.8M |
| Income Tax Expense | $-47.7M | $135.2M | $106.4M | $94.2M | $91.6M | $-83.8M | $0 | $0 |
| Net Income | $487.8M | $396.8M | $329.5M | $58.4M | $216.3M | $288.6M | $125.0M | $32.8M |
| Net Margin | 30.1% | 26.7% | 24.9% | 5.0% | 24.8% | 49.2% | 45.9% | 18.9% |
| EPS (Basic) | $8.13 | $6.56 | $5.38 | $0.98 | $3.71 | $5.09 | $3.01 | $0.90 |
| EPS (Diluted) | $7.96 | $6.41 | $5.23 | $0.93 | $3.51 | $4.79 | $2.67 | $0.83 |
| Shares Outstanding (Basic) | 60.0M | 60.5M | 61.2M | 59.7M | 58.3M | 56.6M | 41.5M | 36.3M |
| Shares Outstanding (Diluted) | 61.3M | 61.9M | 63.0M | 62.6M | 61.6M | 60.2M | 46.8M | 39.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |